SAGE therapeutics is a biopharmaceutical company with the mission of improving brain health. On 11/13/23, SAGE announcted that the US Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to SAGE-718 for the treatment of Huntington's disease (HD). SAGE-718 is an oral therapy that targets NMDA receptor dysfunction related to cognitive impairment.
Read the article here: https://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-announces-us-food-and-drug-administration